Clinical trials: Adult Congenital Heart Disease
Dilated Cardiomyopathy
Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy
A randomised, double-blind, placebo-controlled trial to evaluate the role of intracoronary injection of progenitor cells compared to placebo injection in patients with Dilated Cardiomyopathy who have been pre-treated with G-CSF…
- Trial name
- REGEN-DCM (NCT01302171)
- Testing
- granulocyte colony stimulating factor (GCSF), bone marrow mononuclear cells
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Barts & The London NHS Trust
Heart Defects, Congenital
Feasibility Study of the Adult Congenital Heart Disease-Coping and Resilience (ACHD-CARE) Trial
The psychosocial development of adults with congenital heart disease (CHD) can be challenged by many issues including family overprotection, impaired peer relationships, delayed progression into independent adulthood, and…
- Trial name
- ACHD-CARE (NCT01881893)
- Testing
- ACHD-CARE Program
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- University Health Network, Toronto
Heart Failure
Developing a Non-invasive Cardiac Functional Health Status Measurement Device
This is a single-center, non-randomized study.Enrolled patients will be placed on a tilt table and a stress test will be performed in a total of 4 different positions. Their blood pressure will be measured at each position.
- Trial name
- NCT01877343
- Testing
- CVInsight(TM)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Florida
Heart Failure
SGLT2 for Heart Failure in CHD Patients
Heart failure (HF) in adult patients with congenital heart disease is a major cause of morbidity and mortality. Approximately 30% of patients with significant congenital heart disease will develop signs of heart failure.
- Trial name
- GACH (NCT05897489)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Long QT Syndrome Type 3
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
The primary objective of this study is to evaluate the effect of oral eleclazine on mean daytime QTcF interval after 24 weeks of treatment with elecalzine in participants with long QT syndrome Type 3.
- Trial name
- NCT02300558
- Testing
- Eleclazine
- Where
- 12 sites in United States, Canada and 6 more
- Volunteers
- 41 people
- Sponsor
- Gilead Sciences
Idiopathic Dilated Cardiomyopathy
Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.
Clinical trial phase IIb, double-blind, randomized, controlled with placebo. There is sufficient preliminary evidence to consider intracoronary injection of bone marrow progenitor cells as a viable, safe and beneficial treatment…
- Trial name
- NCT02033278
- Testing
- Infusion of autologous mononuclear bone marrow cells
- Where
- 9 sites in Spain
- Volunteers
- 27 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Ondansetron
Ondansetron and the QT Interval In Adult Emergency Department Patients
The purpose of this study is to assess the use of the medication ondansetron (zofran) in the emergency department. There are studies of the ability of ondansetron to cause a prolongation in the QT interval (a certain measurement…
- Trial name
- NCT01759420
- Testing
- Ondansetron
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- C.R.Darnall Army Medical Center
Death, Sudden, Cardiac, Ventricular Fibrillation
PREVENTION-ACHD Risk Score
Sudden cardiac death (SCD) is one of the major causes of mortality in adults with congenital heart disease (ACHD). Risk stratification for sudden cardiac death in this patient group is challenging and at the current moment there…
- Conditions
- Death, Sudden, Cardiac, Ventricular Fibrillation, Ventricular Tachycardia, Congenital Heart Disease
- Trial name
- PREVENTIONACHD (NCT03957824)
- Testing
- PREVENTION-ACHD risk score
- Volunteers
- 783 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Cardiovascular Diseases, Cardiovascular Abnormalities
The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults
Cardiovascular diseases (CVD), primarily heart disease and stroke, are the leading causes of death and prescription drug use in Canada.
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Heart Attack, Stroke
- Trial name
- NCT03826914
- Testing
- CardioFlex Q10
- Where
- Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Congenital Heart Disease, Congenital Heart Defect
Swiss National Registry of Adults With Congenital Heart Disease
Due to successes in the last decades in pediatric heart surgery and cardiology, 90-95% of the children with congenital heart disease reach adult age.This results in an increasing number of adults or "grown-ups" with congenital…
- Trial name
- SACHER (NCT02258724)
- Where
- 6 sites in Switzerland
- Volunteers
- 5,000 people
- Sponsor
- University Hospital, Basel, Switzerland
Cardiac Amyloidosis, Heart Diseases
N-of-1 for Beta-Blockers in Cardiac Amyloidosis
The study team will generate preliminary data on whether patients with cardiac amyloidosis feel better when their beta-blocker is stopped. To achieve this objective, 20 N-of-1 trials (on vs.
- Conditions
- Cardiac Amyloidosis, Heart Diseases, TTR Cardiac Amyloidosis
- Trial name
- NCT05019027
- Testing
- Beta blocker
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Weill Medical College of Cornell University
Fabry Disease
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease
The purpose of this study is to compare the safety and effectiveness of various doses of Replagal in patients with cardiomyopathy due to Fabry disease.
- Trial name
- NCT00864851
- Testing
- Replagal
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 44 people
- Sponsor
- Shire
Marfan Syndrome
Marfan Syndrome Moderate Exercise Trial II
Marfan syndrome (MFS) is a distinctive connective tissue disorder that affects multiple organ systems including the heart, bones, ligaments, and eyes, and is associated with significant risk of aortic dissection.
- Trial name
- NCT05809323
- Testing
- Exercise Intervention Group, Control Group
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baylor College of Medicine
Marfan Syndrome
Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome.
Marfan syndrome (MFS) is a rare genetic disease (1/5000) characterized by the association of ocular impairment, cardiovascular disease and musculoskeletal disease.
- Trial name
- Marfanpower (NCT03236571)
- Testing
- Rehabilitation program
- Where
- France
- Volunteers
- 28 people
- Sponsor
- University Hospital, Toulouse
Marfan Syndrome
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
Marfan syndrome is an inherited connective tissue disorder with morbidity and mortality from aortic dilation and dissection. The degree of aortic dilation and response to beta-blockade (standard of care) vary in adults with…
- Trial name
- NCT00723801
- Testing
- Atenolol, Losartan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Brigham and Women's Hospital
Congenital Heart Disease
Quality of Life in Young Adults With Congenital Heart Disease
This study aims to evaluate the psychosocial situation of adult congenital heart disease (CHD) patients in terms of health-related quality of life, mental health, academic achievement, and employment status.
- Trial name
- NCT02463292
- Testing
- no intervention
- Where
- Switzerland
- Volunteers
- 325 people
- Sponsor
- University Children's Hospital, Zurich
Congenital Heart Disease
Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
The primary objective is to assess the effect of macitentan 10 mg as compared to placebo on exercise capacity through cardiopulmonary exercise testing.
- Trial name
- RUBATO (NCT03153137)
- Testing
- Macitentan 10 mg
- Where
- 32 sites in United States, Australia and 10 more
- Volunteers
- 142 people
- Sponsor
- Actelion
Congenital Heart Disease
Hepatitis C in Adults Who Underwent Congenital Heart Surgery Before Screening
This is a retrospective chart review. We hypothesize that patients who have undergone congenital heart surgery, prior to screening of blood products have a significant risk of hepatitis C infection and all such patients would…
- Trial name
- NCT00359099
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Emory University
Adult Congenital Heart Disease
Real-World Data on the Effects of Cardiac Resynchronization Therapy in Adult Patients With Congenital Heart Disease
This study aims to evaluate the real-world effects of cardiac resynchronization therapy (CRT) in adult patients with congenital heart disease (ACHD).
- Trial name
- RECORD-CHD (NCT06969924)
- Testing
- Cardiac resynchronization therapy
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Leiden University Medical Center
Epilepsy (treatment Refractory)
Percutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale（PREDICT-PFO Trial）
Patent foramen ovale (PFO) is the most common cause of right-to-left shunt (RLS) in the adult heart, with a prevalence of approximately 25% in the general population.
- Trial name
- PREDICT-PFO (NCT06863350)
- Testing
- patent foramen ovale closure
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sichuan University